1-(4-benzyloxybenzyl)-3-methylthiourea | 1400799-63-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-benzyloxybenzyl)-3-methylthiourea
• 英文别名: 1-(4-Benzyloxy-benzyl)-3-methyl-thiourea；1-methyl-3-[(4-phenylmethoxyphenyl)methyl]thiourea
• CAS: 1400799-63-4
• 化学式: C₁₆H₁₈N₂OS
• 分子量: 286.398
• InChiKey: WTJHYYAEJUIEOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  65.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-苄氧基苯甲醛 在 sodium tetrahydroborate 、 titanium(IV)isopropoxide 作用下， 以 四氢呋喃 为溶剂， 生成 1-(4-benzyloxybenzyl)-3-methylthiourea
  参考文献：
  名称：

  N-methylthioureas as new agonists of retinoic acid receptor-related orphan receptor

  摘要：

  制备了三十二种硫脲衍生物，并评估了它们对视黄酸受体相关孤儿受体α（RORα）的激动活性。将先导化合物CGP52608（1）的3-烯丙基-2-亚氨基-噻唑烷-4-酮部分替换为各种官能团取代的芳香环，从而提高了RORα的激动活性。在制备的衍生物中，1-甲基-3-（4-苯氧基-苄基）-硫脲（32）在RORα激活试验中显示出比CGP52608高2.6倍的激动活性。

  DOI：

  10.1007/s12272-012-0809-0

文献信息

• NOVEL THIOUREA DERIVATIVES AS ACTIVATORS OF RORalpha AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
  申请人：LEE Mi Ock

  公开号：US20180265462A1

  公开（公告）日：2018-09-20

  Provided is a compound activating RORα gene, particularly a JC1 compound containing CGP52608 thiazolidinedione as a lead substance, and a pharmaceutically acceptable salt thereof. The compound is a lipid accumulation inhibitor and applicable to the treatment of metabolic diseases or inflammatory diseases.

  提供的是一种激活RORα基因的化合物，特别是一种含有CGP52608噻唑烷二酮作为主要物质的JC1化合物，以及其药用盐。该化合物是一种脂肪积聚抑制剂，适用于治疗代谢性疾病或炎症性疾病。
• Method for preparing novel crystalline forms of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea
  申请人：Therasid Bioscience Inc.

  公开号：US10995066B1

  公开（公告）日：2021-05-04

  The present disclosure relates to a method for preparing 1-(4-benzyloxy-benzyl)-3-methyl-thiourea and a method for preparing a novel stable crystalline form A of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea.

  本公开涉及一种制备1-(4-苄氧基苄基)-3-甲基硫脲的方法，以及制备1-(4-苄氧基苄基)-3-甲基硫脲的新型稳定晶型A的方法。
• Thiourea derivatives as activators of RORα and pharmaceutical composition containing same
  申请人：Lee Mi Ock

  公开号：US10407388B2

  公开（公告）日：2019-09-10

  Provided is a compound activating RORα gene, particularly a JC1 compound containing CGP52608 thiazolidinedione as a lead substance, and a pharmaceutically acceptable salt thereof. The compound is a lipid accumulation inhibitor and applicable to the treatment of metabolic diseases or inflammatory diseases.

  本研究提供了一种激活 RORα 基因的化合物，特别是一种以 CGP52608 噻唑烷二酮为先导物质的 JC1 化合物及其药学上可接受的盐。该化合物是一种脂质蓄积抑制剂，适用于治疗代谢性疾病或炎症性疾病。
• Polymorphs of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea
  申请人：Seoul National University R&DB Foundation

  公开号：US11390582B2

  公开（公告）日：2022-07-19

  The present disclosure relates to a 1-(4-benzyloxy-benzyl)-3-methyl-thiourea compound in crystalline forms A, B, C, or amorphous form, a method for preparing the compound in the crystalline or amorphous forms, and a use of the compound for preventing or treating a metabolic disease or inflammatory disease.

  本公开涉及结晶形式 A、B、C 或无定形形式的 1-(4-苄氧基苄基)-3-甲基硫脲化合物、制备结晶或无定形形式的该化合物的方法，以及该化合物在预防或治疗代谢性疾病或炎症性疾病方面的用途。
• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES COMPRISING THIOUREA DERIVATIVE
  申请人：SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION

  公开号：US20180235912A1

  公开（公告）日：2018-08-23

  The present invention relates to a novel use of a thiourea derivative and, more specifically, to a pharmaceutical composition for preventing or treating autoimmune diseases comprising a thiourea derivative as an active ingredient. The thiourea derivative according to the present invention can inhibit the transcription of inflammatory genes such as TNF-α, IL-1β, NOS2 and IL-6, and also can inhibit the activity or production of Th17 and increase the activity or production of a regulatory T cell (Treg). Thus, it is expected that the thiourea derivative may be usefully used in a pharmaceutical composition, a health food composition, etc. for the prevention, improvement or treatment of various autoimmune diseases including rheumatoid arthritis.